rofecoxib has been researched along with Osteoarthritis, Hip in 8 studies
Osteoarthritis, Hip: Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 6.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "5), with symptomatic osteoarthritis of hip or knee were included in an open label study with rofecoxib." | 5.11 | Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib. ( Bellamy, N; Bischoff-Ferrari, HA; Good, M; Theiler, R, 2004) |
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 2.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "Rofecoxib and naproxen were generally well tolerated." | 2.70 | Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. ( Amante, C; Chen, SL; Choon, D; Chow, CT; De Tora, L; Genti, G; Laurenzi, M; Lu, HS; Moan, A; Myllykangas-Luosujärvi, R; Pasero, G; Rodgers, DB; Sarembock, B; Vrijens, F; Zerbini, CA, 2002) |
| "Rofecoxib was well tolerated and provided efficacy that was clinically comparable, according to predefined statistical criteria, to that of 150 mg of diclofenac per day in this 1-year study." | 2.69 | Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 ( Bolognese, J; Caldwell, JR; Cannon, GW; Daniels, B; Ehrich, E; Holt, P; McLean, B; Mukhopadhyay, S; Seidenberg, B, 2000) |
| "Rofecoxib was recalled in September 2004 when studies identified increased cardiovascular risk compared with placebo among patients taking rofecoxib." | 1.33 | The patient's perspective on the recall of Vioxx. ( Hawker, GA; Katz, JN; Solomon, DH, 2006) |
| " Adverse events were closely monitored." | 1.32 | Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. ( Bannwarth, B; Dougados, M; Euller-Ziegler, L; Ravaud, P; Rolland, D; Trèves, R, 2003) |
| "Rofecoxib is a highly selective inhibitor of cyclooxygenase-2 used in symptomatic treatment of inflammation and pain in patients with osteoarthritis of the hip or knee." | 1.31 | Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. ( Bischoff, HA; Good, M; Theiler, R; Uebelhart, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Myllykangas-Luosujärvi, R | 1 |
| Lu, HS | 1 |
| Chen, SL | 1 |
| Choon, D | 1 |
| Amante, C | 1 |
| Chow, CT | 1 |
| Pasero, G | 1 |
| Genti, G | 1 |
| Sarembock, B | 1 |
| Zerbini, CA | 1 |
| Vrijens, F | 1 |
| Moan, A | 1 |
| Rodgers, DB | 1 |
| De Tora, L | 1 |
| Laurenzi, M | 1 |
| Bannwarth, B | 1 |
| Trèves, R | 1 |
| Euller-Ziegler, L | 1 |
| Rolland, D | 1 |
| Ravaud, P | 1 |
| Dougados, M | 1 |
| Theiler, R | 2 |
| Bischoff, HA | 1 |
| Good, M | 2 |
| Uebelhart, D | 1 |
| Bischoff-Ferrari, HA | 1 |
| Bellamy, N | 1 |
| Hawker, GA | 1 |
| Katz, JN | 1 |
| Solomon, DH | 1 |
| Smugar, SS | 1 |
| Schnitzer, TJ | 1 |
| Weaver, AL | 1 |
| Rubin, BR | 1 |
| Polis, AB | 1 |
| Tershakovec, AM | 1 |
| Cannon, GW | 1 |
| Caldwell, JR | 1 |
| Holt, P | 1 |
| McLean, B | 1 |
| Seidenberg, B | 1 |
| Bolognese, J | 1 |
| Ehrich, E | 1 |
| Mukhopadhyay, S | 1 |
| Daniels, B | 1 |
| Adler, J | 1 |
4 trials available for rofecoxib and Osteoarthritis, Hip
| Article | Year |
|---|---|
Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.
Topics: Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adminis | 2002 |
Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Computer Terminals; Female; Hip Joint; Humans; Knee J | 2004 |
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Double-Blind Method; Female; Humans; Lactones; Male; Midd | 2006 |
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double- | 2000 |
4 other studies available for rofecoxib and Osteoarthritis, Hip
| Article | Year |
|---|---|
Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients.
Topics: Administration, Oral; Aged; Ambulatory Care; Cyclooxygenase Inhibitors; Drug Administration Schedule | 2003 |
Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lactones; Male; Middle Aged; Osteoart | 2002 |
The patient's perspective on the recall of Vioxx.
Topics: Aged; Cardiovascular Diseases; Communication; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control | 2006 |
Arthritis: what it is, why you get it and how to stop the pain.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy | 2001 |